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ABSTRACT 
Background: Acute myocardial infarction (AMI) and other forms of myocardial 
acute oxidative stress are associated with variable “shedding” of the endothelial 
glycocalyx (GCS) which can be quantitated ex vivo by release into plasma of 
glycocalyx components such as Syndecan-1 (SD-1). Previous studies have implicated 
release of both catecholamines and BNP as potential accentuating factors in GCS: 
since these are prominent aspects of the pathogenesis of Takotsubo cardiomyopathy 
(TTC), we hypothesised that TTC is associated with increased GCS and the extent of 
GCS is predictable on the basis of NT-proBNP and catecholamine releases.  
Methods: SD-1 concentrations were measured in 48 TTC patients acutely and after 3 
months, and compared with those in 12 healthy controls, and 17 patients with AMI. 
Correlations were sought between SD-1 levels markers of severity of TTC episodes in 
individual patients. 
Results: Acute SD-1 concentrations in TTC patients were elevated significantly (p < 
0.0001, 1-way ANOVA) compared to control values. There were no significant 
correlations between SD-1 concentrations and any markers of severity of acute TTC 
episodes, such as NT-proBNP or catecholamine release. Over 3 months, SD-1 
concentrations fell significantly (p = 0.0002) to approximately the same values as in 
control subjects. 
Conclusions: TTC is associated acutely with a marked increase in GCS. Potentially, 
GCS might contribute to increased coronary vascular permeability in TTC, thus 
dissociating development of myocardial oedema from severity of associated 
inflammation. Prevention of GCS represents a potential therapeutic option in TTC. 
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MAIN TEXT 
1. Introduction 
Takotsubo cardiomyopathy (TTC) or “broken heart syndrome” is a form of 
potentially reversible acute left ventricular systolic dysfunction which affects mainly 
women aged over 50 years, usually after physical or emotional stress and often 
resembles acute myocardial infarction (AMI) clinically [1].  It is interesting to reflect 
that although TTC was first characterised only 24 years ago [2], it is anything but 
rare, accounting for approximately 10% of "heart attacks" in women [3] . It has been 
recently reported in a large cohort study that TTC is associated with a substantial 
early mortality rate due to lethal arrhythmias and cardiogenic shock [4]. In-hospital 
mortality rates are approximately  2-6%, with high levels of residual disability for at 
least 3 months  [3], and high risk of recurrence [5]. There are currently no proven 
strategies for the treatment of acute TTC or for the prevention of recurrence and these 
are urgently required.  
TTC is known to be precipitated by surges of catecholamine release/exposure, in 
ageing (especially female) hearts. Recent studies have suggested that TTC is 
associated with a marked increase in markers of myocardial inflammation [such as 
brain natriuretic peptide (BNP)/NT-proBNP release [6] and prolonged myocardial 
oedema on cardiovascular magnetic resonance (CMR) [7] and with a substantial  
associated reduction   in myocardial phosphocreatine to ATP ratio (PCr : ATP) [8], 
indicative of energetic impairment. 
AMI and other forms of myocardial acute oxidative stress are associated with variable 
“shedding” of vascular and other glycocalyx [9], which controls both permeability 
and shear sensing in the macro-and micro-vasculature. This glycocalyx shedding 
(GCS) can be quantitated by release into plasma of glycocalyx components such as 
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Syndecan-1 (SD-1), which is the most prevalent proteoglycan. Previous in vitro 
studies have implicated release both of catecholamines [10] and BNP [11] as potential 
accentuating factors in GCS: since these are prominent aspects of the pathogenesis of 
TTC, we hypothesised that TTC (i) would be associated with increased GCS both 
acutely and during subsequent 3 months of continued myocardial inflammation and 
(ii) extent of GCS would be predictable on the basis of NT-proBNP and 
catecholamine release.  
2. Methods: The study was designed as a comparison between cases of TTC and 
healthy postmenopausal female controls; a small group of patients with AMI, which is 
known to be associated with SD-1 release [9], served as a comparator group.  
2.1 Patient population 
(a) TTC group.  
Consecutive TTC patients were prospectively identified on the basis of the following 
criteria: (1) chest pain and/or dyspnoea ≥ 30min, (2) ST/T wave changes and/or 
biomarker elevation, (3) periapical or midventricular akinesis/hypokinesis, and (4) no 
evidence for a diagnosis of myocardial infarction on coronary angiography or 
cardiovascular magnetic resonance (CMR).  
(b) Control group.   
The control group of 12 females were recruited via newspaper advertisements. 
Subjects with current or previous symptomatic myocardial ischaemia were excluded. 
(c) AMI group. 
 Patients who had been diagnosed with an AMI (23 ± 6 hours post onset of symptoms) 
were selected (n = 17).  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
8 
 
For both TTC and AMI patients’ blood, sampling for SD-1 levels occurred 1-3 days 
post onset of symptoms. In 36 of 48 TTC patients, the blood samples were taken 
within 24 hours post onset of symptoms.  
This investigation complies with the principles outlines in the Declaration of Helsinki 
and was approved by the Institutional Ethics of Human Research Committee (Central 
Northern Adelaide Health Service: the Queen Elizabeth Hospital and Lyell McEwin 
Hospital; protocol number: 009014). Written informed consent was obtained from all 
participants before study entry.  
2.2 Quantitation of glycocalyx shedding  
Venous blood specimens were collected into EDTA-coated tubes, centrifuged at 4 °C 
at 1000g for 10 mins, and plasma was stored at −80 °C until assay. GCS was 
quantitated via measurement of syndecan-1 concentrations in plasma (sCD138 ELISA 
Kit, Diaclone Research, France). In the TTC patients, these evaluations occurred at 
the time of diagnosis and 3 months thereafter. 
2.3 Relationships between glycocalyx shedding and severity of TTC 
(a) Biochemical correlates 
Plasma concentrations of normetanephrine and metanephrine, non-acidic derivatives 
of norepinephrine and epinephrine, were measured by liquid chromatography/tandem 
mass spectrometry (LC-MS/MS). 
Serial routine biochemical investigations including assays of plasma NT-proBNP 
using immunoassay (Elecsys E 170, Roche Diagnostics, Mannheim, Germany), high 
sensitivity plasma C-reactive protein (hs-CRP) concentrations utilizing a latex-
enhanced immunoturbidometric assay (Olympus au5400, Dallas, Texas, USA), 
Creatine kinase (CK), and troponin T were performed. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
9 
 
(b) Pathophysiological correlates 
The lowest blood pressure during the first 24 hours of admission was obtained from 
patients’ clinical records. Global indices of LV deficit and tissue inflammation were 
derived from echocardiographic and cardiovascular magnetic resonance imaging 
studies.  T2-weighted CMR was performed as previously described utilizing a Philips 
Achieva 1.5 Tesla machine (Best, Netherlands)[7].  T2-weighted signal intensity 
(T2w-SI) was utilized as an index of myocardial oedema/inflammation.   
2.4 Statistics 
Data were analyzed using the SPSS software (version 15, Chicago, Illinois, USA) and 
presented as mean and SD or median and interquartile range depending on data 
distributions.  
Comparisons between SD-1 levels in TTC patients at admission, AMI patients and 
control subjects were performed utilizing 1-way ANOVA. Unpaired t-tests were 
utilized further to compare the differences in SD-1 levels between individual groups 
(controls vs. acute TTC and acute TTC vs. AMI). P values were corrected for multiple 
testing using Bonferroni correction. A separate comparison between acute vs. 3 month 
TTC values was analyzed utilizing paired t-tests. 
In order to test the hypothesis that the extent of GCS is correlated with markers of 
TTC severity, syndecan-1 concentrations were correlated with (i) acute LV function, 
(ii) lowest blood pressure (BP) on admission, (iii) peak plasma catecholamine levels, 
and (iv) hs-CRP, NT-proBNP concentrations, and T2 signal intensity (T2-SI)   via 
linear regression or Spearman’s correlation as appropriate. To evaluate potential 
determinants of acute GCS, backwards stepwise multiple logistic regression was 
performed. Parameters for inclusion in multivariate analysis were chosen on the bases 
of (i) a priori hypothetical rational for association (age, lowest BP within 24 hours of 
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admission, acute LVEF, Troponin concentrations), and/or (ii) association (p < 0.2) on 
univariate analysis (NT-proBNP, metanephrine concentrations).      
 A value of p < 0.05 was considered significant.   
3 Results 
3.1 Patients’ characteristics 
The clinical characteristics of the study population (TTC, control and AMI reference 
groups) are described in the Table. 48 female patients diagnosed with TTC were 
studied.  There were no differences in age, gender and cardiovascular risk factors 
between the TTC, control and AMI subjects. 
3.2 Glycocalyx shedding in TTC 
(a) SD-1 elevations in TTC  
As shown in Figure 1, the SD-1 concentrations were on average 56 µg/L higher for 
patients in the acute phase of TTC than for healthy subjects [mean 97 ± 65 (SD) vs. 
41 ± 10 µg/L, p = 0.005, unpaired t-test, corrected for multiple testing using 
Bonferroni test].   
(b) SD-1 elevations in AMI 
SD-1 levels were lower in acute TTC compared to acute MI patients (mean 97 ± 65 
vs. 256 ± 208 µg/L, p < 0.0001, unpaired t-test, corrected for multiple testing using 
Bonferroni test). 
(c) Despite incomplete resolution of inflammation, SD-1 concentrations at 3 months 
post TTC attacks fell significantly in comparison with the acute levels (p = 0.0002, 
paired t-test) and did not differ significantly from values as in control subjects (Figure 
2).  
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3.3 Associations between SD-1 concentrations and extent of severity of acute 
episodes 
There were no correlations between SD-1 concentrations and extent of severity of 
acute episodes, as measured by lowest BP within 24 hours of admission, acute LV EF, 
Troponin, NT-proBNP, normetanephrine and metanephrine concentrations. 
On multivariate analyses, the extent of SD-1 elevation in TTC patients was not related 
to any of the chosen markers of attack severity or to patients’ age. 
4. Discussion 
TTC is often associated with hypotension during its acute stages, and with the 
development of myocardial oedema [7]. The extent of hypotension is not well 
correlated with left ventricular systolic dysfunction [12]. While the oedema has been 
ascribed to myocardial inflammation, this association has never been shown to be 
causative. 
In the current study, we have shown that SD-1 release into plasma is markedly 
increased during the acute stages of TTC, and was approximately the same in 
magnitude as in AMI. Furthermore, this release returned to normal levels 3 months 
post onset of TTC. 
Several factors already implicated in TTC are known to activate the process of GCS. 
Notably, both catecholamines and BNP are known stimuli for the process [10, 11]. 
Furthermore, there is considerable evidence that activation of matrix 
metalloproteinases represents a major stimulus for glycocalyx disruption [13], but no 
studies to date have evaluated this potential issue in TTC. 
One residual issue is the precise sequence of biochemical/physiological events in 
TTC. For example, SD-1 release might be a “secondary” event, stimulated via 
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inflammation-mediated BNP release [11]. Alternatively, it could be a “primary” 
mechanistic change, whereby catecholamine effects translate to neutrophil permeation 
of damaged coronary vessels and thus to myocardial inflammation. 
These findings should also focus attention on vascular function in T C. GCS results 
not only in endothelial dysfunction [14] but also in abnormal responses to shear stress 
[15]. A study by Cecchi [16] showed that microvascular coronary reactivity was 
indeed abnormal in TTC, but the cause of this was not evaluated. GCS also facilitates 
monocyte adhesion to the venular endothelium and subsequent transmigration into the 
myocardium [17].  
These findings also have substantial potential clinical applicability. For example, it 
may be that myocardial oedema accounts for impaired ventricular torsion and 
resultant decreases in cardiac output. Oedema within the pulmonary circulation could 
occur without substantial elevation of wedge pressures, via transudation of pulmonary 
capillary fluid. Importantly, ACE inhibitors, which appear to prevent recurrences of 
TTC, may limit matrix metalloproteinase (MMP) activation [18, 19]. Furthermore, 
low dose doxycycline represents a further potential therapeutic avenue via MMP 
inhibition [13]. 
The study has some limitations. The precise time course of release SD-1 was not 
investigated and it is also uncertain whether the process has completely resolved after 
3 months. If indeed this is the case, the reason for hysteresis between inflammation 
and syndecan-1 release is uncertain. Given that the precipitant for TTC episodes was 
in theory a “pulse” release if catecholamines, it would be desirable to compare the 
time course of such a “pulse” with that of onset of glycocalyx shedding. This is in 
practice very difficult, because the time of onset of TTC cannot always be precisely 
estimated, and because only levels of the catecholamine derivatives normetanephrine 
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and metanephrine were measured (and even so, at a single time point). There was also 
an inevitable and variable delay between patient presentation and the diagnosis of 
TTC, so that initial sampling occurred 1-3 days post onset of symptoms: again this 
may have obscured the “time” peak of SD-1 release.   
In conclusion, TTC is associated with acute release into plasma of SD-1. Investigation 
of the possible role of this process in the pathophysiology and potential therapeutics 
of TTC is appropriate. 
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Figure legends:  
Figure1: Plasma SD-1 levels in control subjects, acute TTC, and AMI patients. p < 
0.0001 for heterogeneity (1-way ANOVA); (** = 0.005 for acute TTC vs. controls, * 
< 0.0001 for acute TTC vs. AMI,  unpaired t-test, corrected for multiple testing using 
Bonferroni test). 
Figure 2: Changes in plasma syndecan-1 levels in individual TTC patients over 3 
months’ recovery (p = 0.0002, paired t-test). 
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Table: Patients’ characteristics. There were no statistically significant differences 
between groups in any parameter. 
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Figure 1 
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Figure 2 
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Table: Patients’ characteristics. There were no statistically significant differences 
between groups in any parameter. 
 
Parameters 
TTC 
(n = 48) 
Controls 
(n = 12) 
AMI 
(n = 17) 
Age (mean ± SD) 67 ± 14 64 ± 7 70 ± 14 
Current/past smoking (%) 28 11 25 
Hypertension (%) 63 32 63 
Diabetes mellitus (%) 28 21 13 
Dyslipidemia (%) 40 32 31 
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Highlights: 
 TTC is associated acutely with marked increase in GCS.  
 GCS might contribute to increased coronary vascular permeability in TTC, 
thus dissociating development of myocardial oedema from severity of 
associated inflammation. 
 Prevention of GCS represents a potential therapeutic option in TTC. 
